Objective-To study maternal and fetal outcome of pregnancy in patients with lupus who were exposed to hydroxychloroquine (HCQ). Methods-The case records of women (n = 33) exposed to HCQ during their pregnancies (n = 36) and of 53 control patients from a single lupus pregnancy centre were reviewed to determine lupus activity, obstetric experience, and inflint outcome. Results-HCQ was not apparently teratogenic. Lupus activity and obstetric outcome in the two groups were similar.
Conclusion-HCQ continuation is probably safe during pregnancy in patients with lupus, but there is no obvious advantage in commencing treatment.
(Ann Rheum Dis 1996; 55: [486] [487] [488] Over the past few decades, convincing evidence has accumulated for the efficacy of antimalarial drugs in the treatment of systemic lupus erythematosus (SLE) and discoid lupus erythematosus (DLE).1 2 Anxiety over their possible teratogenic effects on the developing eye3 and in causing chromosomal damage4 in the early conceptus have discouraged their administration in pregnancy. However, limited safety data have been building up through anecdotal reports and with the publication of Parke's more extensive experience. [5] [6] [7] It has been our policy in our Lupus Pregnancy Clinic to permit use of hydroxychloroquine (HCQ) to continue, and occasionally to permit usage to commence during gestation. We present here our experience in 36 pregnancies in lupus patients, which 
Results
Demographic data of the patients and controls in relation to age and race, mean duration of lupus, antibody pattern, average prednisolone dose, and disease activity at the onset of pregnancy were comparable. The pattern of previous obstetric experience was similar: 42% of the HCQ group had live births, compared with 36% of the controls.
Of the 36 pregnancies in 33 patients with HCQ exposure that were reviewed, 22 were exposed to HCQ 200 mg/day and 14 to 400 mg/day at some point during gestation. The figure illustrates the profiles of exposure.
The mean duration of exposure to HCQ in pregnancy was 28-4 (SD 10-75) weeks, and the average antenatal exposure was 24-4 (20.08) months. Original indications for the drug were cutaneous rash in every case, with additional arthritis in 18 and serositis in one patient. _____m m There are theoretical reasons, therefore, for maintaining HCQ in SLE pregnancy, and 24 of our patients continued to take the drug which had been previously commenced. Seven of those in our series initiated treatment in pregnancy; there were no ill effects observed in mothers or babies in this subgroup. Overall, our experience in a relatively small series of patients demonstrates that continuing HCQ appears to be safe in lupus pregnancy, though there is no obvious advantage in initiating treatment with the drug. It is possible, in view of the retrospective nature of the study, that the number of early miscarriages was underestimated. This may be ofimportance, as HCQ has been shown to induce chromosomal abnormalities. In addition, accurate assessment of vision in young children is difficult to undertake, and we intend to follow up the babies of patients exposed to HCQ 'in utero' in the future.
review of a series of 36 cases. 
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